Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Streamlining Detection Strategies for Signal Detection

Posted on September 29th, 2017 by in Pharma R&D

Widespread underreporting is often cited as a factor that curtails the analytical value of data from spontaneous reporting systems. Voluntary submission of reports is a core feature of these systems but it also means that not all events suspected to be associated with a medicinal product are documented and brought to the attention of authorities and marketing authorization holders – Continue reading “Streamlining Detection Strategies for Signal Detection” »

The Importance of Selecting The Most Promising Drug Target

Posted on September 27th, 2017 by in Pharma R&D

The growing economic pressure due to late-stage drug approval failures has been forcing drug discovery and development scientists to adapt their strategies in order to increase their chances of success. Continue reading “The Importance of Selecting The Most Promising Drug Target” »

Reducing Adverse Event Risk

Posted on September 25th, 2017 by in Pharma R&D

In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” Continue reading “Reducing Adverse Event Risk” »

Is the Pharma Industry Missing the Big Picture?

Posted on September 22nd, 2017 by in Pharma R&D

There is a disconnect between how drugs are developed and how they are used. In the traditional method of target-oriented development, each new candidate drug is scrutinized in a handful of interactions with desirable and undesirable targets. Continue reading “Is the Pharma Industry Missing the Big Picture?” »

  1. 1
  2. 2
  3. 3
  4. 4